Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pertuzumab
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Neratinib and Paclitaxel with or without Pertuzumab and Trastuzumab before Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Breast Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0537, NCI-2017-00813, NCT03101748
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER2-Positive Stage II-IV Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 12147, NCI-2012-02371, 105932, 109681, 119638, NCT01730833
Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-497, NCI-2013-01110, ML28193, NCT01796197
FDG-PET in Predicting Treatment Response in Patients with Newly Diagnosed Stage II-IV Breast Cancer Receiving Pertuzumab and Trastuzumab Prior to Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 026, NCI-2014-01543, NCI-2014-00245, NA_00080994, NCT01937117
Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-409, NCI-2015-00454, NCT02326974
Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 14-67, NCI-2015-02066, NCT02436993
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TDM4529g, NCI-2009-01154, BO25430, 2010-021067-32, NCT00781612
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00014171, NCI-2017-00510, NCT02693535
Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-024, NCI-2015-00627, ML29407, NCT02390427
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29831, NCI-2015-02225, 2015-002113-29, NCT02605915
Pertuzumab and Trastuzumab in Treating Patients with HER2 Positive Breast Cancer with Untreated Brain Metastasis
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00061309, NCI-2016-00827, NCT02598427
Start Over